MyoMed-205 is a small molecule that inhibits MuRF1 (TRIM63) activity and MuRF1/MuRF2 expression.
MyoMed-205 has improved serum stability when compared with initial lead compound ID#704946.
MyoMed-205 attenuates induction of MuRF1 in tumor stressed muscles. MyoMed-205 also rescues citrate synthase and complex-1 activities in tumor-stressed muscles.
MyoMed-205 attenuates skeletal muscle strength loss in mouse model for type 2 diabetes mellitus (T2DM), with no significant effects on serum glucose.
MuRF1 (muscle-specific RING finger protein-1) is a muscle-specific ubiquitin ligase that regulates muscle catabolism during chronic wasting states, both MuRF1 and MuRF2 participate in glucose and, also, in lipid regulation.
